ImmunoGenesis has dosed the first participant in its Phase Ia/Ib clinical trial of IMGS-001 for the treatment of relapsed or refractory advanced solid tumours.
The first patient was dosed at the University of Texas MD Anderson Cancer Center in Houston, US.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The first-in-human, multicentre, open-label dose escalation and expansion trial will evaluate the pharmacokinetics, safety and initial anti-tumour activity of IMGS-001.
It includes adult subjects with locally advanced or metastatic solid tumours that are refractory to standard-of-care therapy.
In the dose escalation part of the trial, ImmunoGenesis plans to include patients with tumours such as colorectal, ovarian and triple-negative breast cancer.
A lead asset of the company, IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) monoclonal antibody.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe antibody has cytotoxic effector activity and is intended for treating immune-excluded cancers that are resistant to current immunotherapies.
In preclinical research, IMGS-001 was shown to offer improved response rates in head-to-head studies versus existing immunotherapies.
In June 2023, the company received an investment of $4.5m from the Cancer Focus Fund for its Phase Ia/Ib trial of IMGS-001.
ImmunoGenesis president and CEO James Barlow said: “Many tumours are not responsive to the current immunotherapies, representing a significant unmet need.
“We believe that this study will deliver initial proof of concept for our groundbreaking multitasking approach of using a single molecule to address immunosuppression and PD-1 pathway blockade.”
